Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells.

Human gene therapy - 20 Oct 1996

Arienti F, Sulé-Suso J, Belli F, Mascheroni L, Rivoltini L, Melani C, Maio M, Cascinelli N, Colombo M P, Parmiani G

Abstract excerpt

We have immunized advanced melanoma patients with a HLA-A2-compatible human melanoma line genetically modified to release interleukin-2 (IL-2), to elicit or increase a T cell-mediated anti-melanoma response that may affect distant lesions. Twelve stage-IV patients were injected subcutaneously at days 1, 13, 26, and 55 with IL-2 gene-transduced and irradiated melanoma cells at doses of 5 or 15 x 10(7) cells. Both...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antibodies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antigens, Neoplasm

Share to Cell Line, Transformed

Share to Interleukin-2

Share to Leukocytes, Mononuclear

Share to Melanoma

Share to Phenotype

Source

Identifiers

PMID: 8930655
DOI: 10.1089/hum.1996.7.16-1955

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells.PMID 8930655Read ↗

A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine.Semantic proximity Read ↗

Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.Semantic proximity Read ↗

Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.Semantic proximity Read ↗

Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma.Semantic proximity Read ↗

Growth and autologous tumor lysis by tumor-infiltrating lymphocytes from metastatic melanoma expanded in interleukin-2 or interleukin-2 plus interleukin-4.Semantic proximity Read ↗

A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer.Semantic proximity Read ↗

Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.Semantic proximity Read ↗

Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.Semantic proximity Read ↗

Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.Semantic proximity Read ↗

High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy.Semantic proximity Read ↗

Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.Semantic proximity Read ↗

Enhanced interleukin-2 production in human tumor-infiltrating lymphocytes engineered by 3'-truncated interleukin-2 gene.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.